Firebrick Pharma (ASX:FRE) announced a move to bolster its international presence by appointing Nilesh Wadhwa as the new Head of Business Development and Licensing.
The appointment, effective from April 1, follows a comprehensive international search and signals a transformative phase for the Australian-based pharmaceutical company.
Wadhwa brings a pedigree to the role, boasting approximately 30 years of high-level experience in pharmaceutical partnering and market expansion.
His career includes leadership tenures at global healthcare giants such as Johnson & Johnson, Sanofi, Takeda Pharmaceuticals, and Alembic Pharmaceuticals, where he navigated complex cross-border transactions across the Asia-Pacific, US, and European markets.
The company has set a target to expand the market reach of its flagship product, Nasodine, increasing its availability from three countries to as many as ten within the next three years.
The expansion is part of a broader vision to grow the company's portfolio from two products to four over the same period.
Dr Peter Molloy, Executive Chairman of Firebrick Pharma, emphasised that Wadhwa joins at a "pivotal time" as the company seeks to secure critical licensing agreements and regulatory approvals globally.
Wadhwa noted that the company's innovative portfolio offers a unique opportunity to drive long-term shareholder value.
Based in Australia, Wadhwa will spend the coming months in transition before officially spearheading the company's drive for international commercial success.